Organoid models for non-alcoholic fatty liver disease
2023
Hubrecht Institute, Utrecht, Netherlands
The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here, the researchers use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis. Screening of drug candidates revealed compounds effective at resolving steatosis. The researchers present FatTracer, a CRISPR organoid screening platform. From a screen targeting 35 genes implicated in lipid metabolism and/or NAFLD risk, FADS2 (fatty acid desaturase 2) emerged as an important determinant of hepatic steatosis. These organoid models facilitate the study of steatosis aetiology and drug targets.
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
Benedetta Artegiani, Delilah Hendriks, Hans Clevers
Added on: 03-15-2023
[1] https://www.nature.com/articles/s41587-023-01680-4[2] https://www.drugtargetreview.com/news/108559/researchers-develop-organoid-models-to-study-non-alcoholic-fatty-liver-disease/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Newsletter+9+-+Unsponsored+-+09.03.2023&utm_term=Stopping+immune+cell+leakage+from+tumours+could+improve+skin+cancer+treatment&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=RZuQN4YVNvhYXveCUe3BbZP1hPziuyv4yNteYz1meND%2bJaXkkwhOh2jj%2fA55EG3wo068S%2f5q832FUYCTZRVDEOsSjR6pC6O4USy25rB5%2b7UyftTqPLpNWUjKmqbrvBgt1MfEfUNvVPj8uwkJMf0%2fQXt%2beBZhI%2fjibzWu3VjFeCLksFVolumK2VyWb2B7oJfE8kxjrUWSGVwi9bYp5IqnioBkpZkr1lEIZpBmT959Uyg%3d
